KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

Palvella Therapeutics (PVLA) Research & Development: 2014-2024

Historic Research & Development for Palvella Therapeutics (PVLA) over the last 11 years, with Dec 2024 value amounting to $2.5 million.

  • Palvella Therapeutics' Research & Development rose 108.91% to $2.5 million in Q4 2024 from the same period last year, while for Dec 2024 it was $8.2 million, marking a year-over-year decrease of 7.30%. This contributed to the annual value of $8.2 million for FY2024, which is 7.30% down from last year.
  • As of Q4 2024, Palvella Therapeutics' Research & Development stood at $2.5 million, which was down 20.08% from $3.2 million recorded in Q3 2024.
  • In the past 5 years, Palvella Therapeutics' Research & Development ranged from a high of $18.9 million in Q3 2021 and a low of -$28.6 million during Q4 2023.
  • Moreover, its 3-year median value for Research & Development was $10.8 million (2022), whereas its average is $5.8 million.
  • Its Research & Development has fluctuated over the past 5 years, first crashed by 313.41% in 2023, then soared by 108.91% in 2024.
  • Palvella Therapeutics' Research & Development (Quarterly) stood at $10.6 million in 2020, then skyrocketed by 44.63% to $15.4 million in 2021, then dropped by 12.87% to $13.4 million in 2022, then plummeted by 313.41% to -$28.6 million in 2023, then soared by 108.91% to $2.5 million in 2024.
  • Its last three reported values are $2.5 million in Q4 2024, $3.2 million for Q3 2024, and $1.4 million during Q2 2024.